Rheumatology

Throughout the pandemic, rheumatologists have been concerned that their patients may be at risk of developing more severe forms of the COVID-19 disease as a result of their rheumatic disease or treatment.

“This class of medication provides an alternative therapeutic option for those that have an inadequate response to conventional DMARDs or biologic therapy.”

Terence Rooney, MD, discusses the ongoing STAR study in depth and the potential of guselkumab to improve axial psoriatic arthritis.

People with rheumatoid arthritis are at increased risk of osteoporosis. Test your knowledge of how the risk of osteoporosis can be minimized in these patients.

Kim Bennell, PhD, discusses her study “Effectiveness of an Unsupervised Online Yoga Program on Pain and Function in People With Knee Osteoarthritis: A Randomized Clinical Trial.”

Although results are promising, findings should be interpreted with caution, as the study was underpowered and terminated early due to the COVID-19 pandemic.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending September 24, 2022.

Bonnie L Bermas, MD, discusses the ways in which the Supreme Court decision to overturn Roe v Wade will change the way rheumatologists are able to care for their patients.

An expert in lupus management provides insight into her treatment approach for a 24-year-old African American female diagnosed with lupus nephritis.

Lupus Case Scenario: Patient History and Presentation

Although results were associative rather than causative, a decrease in BMI may prevent, delay, or slow the structural defects in knee osteoarthritis.

"Dactylitis is considered a core domain of musculoskeletal symptoms in psoriatic arthritis and is important for both patients and physicians when developing treatment strategies.”

The FDA approved risankizumab in June for adult patients with Crohn’s disease, representing the first IL-23 treatment to be approved for this patient population.

Fatigue, a highly multifactorial manifestation of lupus, can be related to disease activity or independent of the disease itself. Investigators determined whether fatigue could be a significant confounder of Physician Global Assessment ratings.

Despite worldwide trend data, incidence trends for dermatomyositis do not show increases among the study population.

"Online interventions have the potential to reach a wide audience, allowing exercise to be undertaken from the comfort and convenience of home and thereby overcoming some of the barriers to exercise reported in the osteoarthritis population.”

The highly encouraging results of the small study may lead to a new therapeutic approach in lupus. However, long-term safety and efficacy need to be evaluated in a larger cohort.

Rebecca Shepherd, MD, MBA, FACR, FACP, discusses the American College of Rheumatology's 2022 Rheumatic Disease Report Card in depth, including what can be done to improve scores and the next steps for her team.

Drs Orrin M. Troum and Jeff R. Peterson discuss infusion reactions associated with pegloticase and the impact of immunomodulators when used with pegloticase in gout.

Orrin M. Troum, MD, and Jeff R. Peterson, MD, discuss challenges with gout treatment.

Orrin M. Troum, MD, discusses methods and results of the MIRROR study in gout.

The Rheumatology Research Foundation has recently announced a grant, called the Community Practice Innovation Award, which focuses on supporting rheumatology practitioners to conduct their crucial, and potentially life-changing, research.

CLEC2B, a key gene linked to ferroptosis regulators in psoriatic arthritis, is differentially expressed in a variety of cancers and is associated with immune cell infiltration as well as immune checkpoints.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending September 17, 2022.

Roy M. Fleischmann, MD, and Joel M. Gelfand, MD, MSCE, FAAD, address the importance of clinician confidence in biosimilars.

The guidelines will provide more options for the treatment and prevention of glucocorticoid-induced osteoporosis and will inform rheumatologists about the requirements for anti-resorptive therapy after anabolic agents are discontinued.

Anne E. Winkler, MD, PhD, MACP and Kristi V. Mizelle, MD, MPH, FACR hypothesize about the role and future of a treat to target approach in patients with lupus.

Kristi V. Mizelle, MD, MPH, FACR shares her treatment goals and discusses the patient characteristics she factors when deciding on a choice of treatment for her patients.

Bimekizumab provided maintenance of completely clear skin and health-related quality of life in most patients with moderate-to-severe plaque psoriasis over a 3-year period.

Results were based on the phase 4 MIRROR trial, which analyzed differences in treatment response for concomitant therapy compared with placebo in adults with uncontrolled gout.